>Enzyme-Linked Immunosorbent Assay (ELISA) Service
Enzyme-linked immunosorbent assays (ELISA) have been around as one of the primary methods of analyte detection for decades. As the workhorse experiment of any drug development research, high quality and reliable ELISA data is critical for scientific understanding and further investigations.
ACRO's advantage comes from our skilled and experienced staff scientists, large catalog of in-house produced proteins, antibodies including anti-idiotype antibodies as well as our ready-to-use ELISA kits.
We provide a comprehensive ELISA bioassay method development service, including method development, validation, transfer, and kit development, according to each of your needs to help you accelerate your drug development process!
ACROBiosystems provides high-quality absorbance, fluorescence and luminescence measurements by employing SpectraMax i3x system (Molecular Devices). ACROBiosystems has also acquired the ScanLaterTM Western Blot expansion as well as the Alpha Screen 384 STD detection cartridge providing our customers multiple options of analysis.
Sensitivity across spectrum with Spectral Fusion™ Illumination
Expanded dynamic range with cooled PMT
Cartridges for FP, AlphaScreen and Western Imaging
Based on the SpectraMax i3x system, ACROBiosystems provides biomedical research and development services for customers seeking quantification and detection of antibodies-antigen interaction. Other services inlcude but are not limited to anti-drug activity (ADA), PK/PD assays as well as antibody screenings.
ACROBiosystems provides a comprehensive range of ELISA bioassay method development services starting from assay reagents to sample detection！
One-stop ELISA bioassay method development service
We provide screening services including peptide screening and antibody screening using common methods like competitive ELISA.
For example, we can perform a screening assay for peptide samples using ACROBiosystem's own Anti-SARS-CoV-2 Neutralizing Antibody Titer Serologic Kit (Cat#: RAS-N022).
The microplate in the kit has been pre-coated with Human ACE2 protein. First serum samples, Positive control, Negative Control are added to the wells followed by addition of HRP-SARS-CoV-2 Spike RBD. The presence of neutralizing antibodies in samples will compete with ACE2 for HRP-SARS-CoV-2 Spike RBD binding. The intensity of assay signal decrease proportionally to the presence of Anti-SARS-CoV-2 neutralizing antibody.
Fig1. Positive reference for anti-SARS-CoV-2 neutralizing antibody concentrations (μg/mL) for peptide 9 screening (SpectraMax i3x).
Fig2. Sample screening for peptide 9 (uM) using anti-SARS-CoV-2 neutralizing antibody titer serologic Kit (Cat#: RAS-N022) (SpectraMax i3x).
Fig3. Different anti-BCMA antibodies have different neutralization ability for BCMA and BAFF.
ln addition to antigen affinity screening, affinity of antibody to Fc receptors and C1q is responsible for cell killing via ADCC/ADCP and CDC effects respectively. Therefore testing association of Fc receptors and C1q is necessary during the development phase of antibody drug candidates.
Fig4. Standard curve of mouse complement C3a to determine the concentrations of C3a in client mouse plasma samples (SpectraMax i3X).
We can perform a binding assay for Human TROP-2 and a client’s antibody to test the eﬃcacy of the provided antibody using our own Human TROP-2 / TACSTD2 Protein, His Tag (Cat#: TR2-H5223). The microplate is coated overnight with TROP-2. The sample antibody is added to the wells, and subsequently the secondary HRP conjugated Goat Anti-Mouse IgG is added. After the primary antibody from the client binds to TROP-2 the HRP secondary antibody will bind to the primary, and following the addition of TMB the intensity of the signal will be proportional to the concentration of primary antibody.
Fig5. Binding curve comparing the concentration of anti-TROP-2 antibody (nM) to the optical density to determine the EC50 (SpectraMax i3x).
An idiotope is the unique set of antigenic determinants (epitopes) of the variable portion of an antibody. An anti-idiotypic (Anti-ID) antibody binds to the idiotope of another antibody, usually an antibody drug, which makes it a very powerful tool for antibody drug development, especially for immunogenicity and PK/PD analysis.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-aﬃnity anti-idiotypic antibodies and ADA/PK services.
Fig6. Immobilized Adali**mab at 1 µg/ml, add increasing concentrations of anti-Adali**mab antibodies (Cat. No. ADB-Y19, 10% human serum) and then add biotinylated Adali**mab at 5 µg/ml. Detection was performed using HRP-conjugated
ACRO has developed conjugated magnetic beads which can be used in beads based ELISA.
This web search service is supported by Google Inc.